Capstone Investment Advisors
BMRN icon

Capstone Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capstone Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,200
Closed -$368K – 1683
2020
Q4 		$368K Sell
4,200
-5,200
-55% -$412K ﹤0.01% 1320
2020
Q3 		$715K Buy
9,400
+5,600
+147% +$567K ﹤0.01% 1099
2020
Q2 		$469K Buy
+3,800
New +$378K ﹤0.01% 1108
2015
Q2 		– Sell
-11,300
Closed -$1.41M – 292
2015
Q1 		$1.41M Buy
+11,300
New +$1.2M 0.02% 221

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's BMRN Position: Q2 2024 in Review

Capstone Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 10,900 shares — an estimated $952K sold.

Capstone Investment Advisors first reported a position in BMRN in Q1 2015 and held it in 24 quarters. The position peaked at $3.02M in Q1 2019. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Capstone Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 10,900 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $952K.
  • Capstone Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 24 quarters.
  • Capstone Investment Advisors's BioMarin Pharmaceuticals position peaked at $3.02M in Q1 2019.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.